- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Martin Shkreli
Recent news which mentions Martin Shkreli
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
July 04, 2025
From Benzinga
'Pharma Bro' Martin Shkreli Says 'Good Chance' Inmune Bio Stock Will Slip 90% On Monday
July 04, 2025
From Benzinga
Everyone Talked About Nvidia, Apple And Tesla, But This One Tech Stock Has Left Them All Behind In 2025
July 04, 2025
From Benzinga
From Benzinga
Cathie Wood Sells Tesla Stock As Chinese Rivals Gain Ground — Ark Dumps Palantir Amid Privacy Concerns
June 02, 2025
From Benzinga
'Pharma Bro' Martin Shkreli Sees $10 Trillion Potential In Palantir, But Cautions: 'One Bad Quarter And It's Down 50%'
June 02, 2025
From Benzinga
From Benzinga
Palantir's $4 Million ARPC Estimate 'Flawed,' Says 'Pharma Bro' Martin Shkreli, But 'I Wouldn't Bet Against Them'
March 13, 2025
From Benzinga
Quantum Computing Stocks RGTI, QUBT, IONQ, QBTS Cheer Microsoft's 'Majorana 1' Launch: Satya Nadella Calls It A 'Physics And Fabrication Breakthrough'
February 20, 2025
From Benzinga
'Pharma Bro' Martin Shkreli Slams Microsoft's Quantum 'Breakthrough,' Predicts IONQ And RGTI Will Plummet As Tech Falls Behind
February 20, 2025
From Benzinga
'Pharma Bro' Martin Shkreli Defends Palantir's Valuation Amid 24% Surge, Says AI Firm's Cash Flow Justifies 'Expensive' Price
February 05, 2025
From Benzinga
Martin Shkreli Calls IonQ And Rigetti 'Best Shorts' Despite Recent Stock Gains, Cites Offline Quantum Systems
January 22, 2025
From Benzinga
From Benzinga
'Pharma Bro' Martin Shkreli Predicts Liquidation Doom For MicroStrategy Amid Fall Below $300, Says Bitcoin Will Hit $250K Without Michael Saylor
December 30, 2024
From Benzinga
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today
November 25, 2024
From Benzinga
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update
November 25, 2024
Tickers
SAVA
From Benzinga
'Pharma Bro' Martin Shkreli Loses Appeal: Supreme Court Imposes $65M Fine, Issues Lifetime Ban From Pharma Industry
October 08, 2024
Tickers
NEWS
From Benzinga
DJT 'TrumpCoin' Allegedly Launched By Martin Shkreli With Barron Trump's Help Tanks 98%
August 06, 2024
From Benzinga
Elon Musk, Warren Buffett, Nancy Pelosi, Jensen Huang, Michael Saylor: Who You Sitting By On A Plane For A 10-Hour Flight?
July 09, 2024
From Benzinga
Allegations Of TrumpCoin's Creation Stir Controversy: 'Keys Are With Trump' Says Martin Shkreli
June 26, 2024
Tickers
NEWS
From Benzinga
From Benzinga
'TrumpCoin' Was Launched By Barron Trump With Donald Trump's Approval, Martin Shkreli Alleges
June 20, 2024
From Benzinga
'Pharma Bro' Martin Shkreli Reportedly Created Trump-Themed DJT Token: 'I Created It With Barron'
June 19, 2024
From Benzinga
From Benzinga
'Pharma Bro' Martin Shkreli Cannot Return To Drug Industry Ever: Court Upholds Lifetime Ban
January 24, 2024
Tickers
NEWS
From Benzinga
Sam Bankman-Fried's Guilty Verdict Stirs Crypto Community Reactions: 'Pharma Bro' 'Feels Bad For Him' Says 'No Victory For Anyone Here'
November 03, 2023
From Benzinga
Mark Cuban Suggests A 'Netflix Model' To Change US Healthcare And Pharmaceutical Industry
June 15, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.